As I promised I post here my market DD of OZSC. Read in detail about their products and the associated market potential. Their products feedback is fine so far as I know. As a medical researcher I am interested in their ongoing products and believe in its great market potential. That is why I will invest in this company for at least 2~3 years! They have pretty good patents and going to announce and update their new products. I have many images but sorry this forum does not accept images so I have no way to post those images.
Headquarters West Palm Beach, FL Stock
Symbol OTCQB:OZSC
Shares Outstanding ~29.6 Million
Gross sales of $228K (By Q3-2018).
Inside Ownership ~84.1%
Near-term commercialization ? Will Launch several new products in H2-2019, 2020.
The Company has 21 Issued patents, more pending and in process. ? Key claims around an inflatable device being delivered and inflated in the disc space. ? Device is then filled with an in situ setting polymer. ? Focus is on access, exposure, and implant delivery to the intervertebral disc space. ? Endoscopic approach, preparation, and implant delivery. ? Surgical instruments, retractor, nerve monitoring, implants are all covered with various IP. Patents Covering Inflatable Balloon Technology No. of Patents 6 Patents Covering Endoscopy No. of Patents 5 Patents Covering MIS Facet Fixation Device No. of Patents 2 Patents Covering Expandable Ratcheting Portfolio No. of Patents 7 Patents Covering Cervical Compression Plate No. of Patents 1 Ozop is a technology leader in the MIS spine implant market, and will continue to seek patents (in the US and abroad) to advance its robust intel
Ozop offers a full line of implants which can be used in +80% of all surgical spine cases. ? Anterior cervical spine cases (ACP, CIB). ? Posterior lumbar Interbody Fusion (PLIF). ? Transforaminal Interbody Fusion (TLIF). ? Anterior Lumbar Interbody Fusion (ALIF). ? Lateral Lumbar Interbody Fusion (LLIF). ? Lateral Buttress Plate. ? Open and MIS Pedicle Screws. Initial orders of sets delivered March 2019. ? Ramp up in sales commencing ? All FDA approved, full range of sizes. ? Low overhead advantage – manufacturer direct pricing. ? Focus on Ambulatory Surgery Centers (ASCs) – truncated vendor approval process, price sensitive buyers ? Stand-alone Expandable ALIF Cage ? Spine Endoscopes ? Balloon Lumbar Interbody Fusion (BLIF™)
Stand-alone Expandable ALIF Cage. ? Anticipated market entrance ? Customer base of initial users committed. ? High margin: $6,200 - $12,000; +90% gross margin. ? Expandable mechanism applicable for other interbody implants. ? Custom fit because adjusts to patients’ anatomy. ? Allows tensioning of spinal ligaments which aids early pain relief post-op and spinal stabilization. ? Easy, complete graft delivery within the implant.
Spine Endoscopes. ? Identified customer base. ? Competitors’ endoscopes offer limited working channel options due to size limitations. ? Ozop system enables multiple options through the scope. ? BLIF development will allow implant delivery through the same working channe
Balloon Lumbar Interbody Fusion (BLIF™) Planned 2020 Introduction; Changing the Future of Spine Surgery. ? The First Truly MIS Implant Solution. ? Lateral spine fusion incision requires 4 inches, anterior approaches can exceed 8 inches. ? Spinal endoscopy adoption has been limited by the size of the interbody implant. ? Ozop’s device is expected to require.
Surgeries to address various neck and back ailments are a huge market. ? Neck and low back pain cost the US more than $87.6 billion per year.(1) ? US market for endoscopic devices expected to reach almost $17 billion by 2021 (from $13 billion in 2016).(2) ? The spinal implant market was over USD $9 Billion in 2017, and is expected to surpass $10.2 Billion by 2022.(3) ? MIS spine surgery has grown more slowly than other specialties due to the size of the implants and the surgical access required. ? Surgeons will have a reason to learn endoscopic spine surgery when they can perform the whole procedure (including the implant) through a small keyhole opening.
The market is moving from Open Spine Surgery to Minimally Invasive Spine Surgery. ? There were 794,000 spinal fusion procedures in the US in 2013 and estimated to increase to ~1.1 million by 2020.(1) ? True MIS (endoscopic) spine surgery has been limited to tissue and bone resection due to the size of the implants and incomplete delivery techniques (implant & bone graft). ? Goal is to minimize the size of the incision, muscle splitting and tissue manipulation. ? Less tissue trauma means less pain, bleeding and anesthesia time, shorter hospital stays, faster patient recovery and lower rates of complication.
MIS Surgery is Superior to Open Surgery for several reasons: ? Lower infection rate.(1) ? Similar fusion rate with better functional outcome, less blood loss, shorter ambulation, and hospital stay; did not increase the complication or reoperation rate.(2) ? Each 30 min increase in OR time and open surgical approach were independently associated with increased risk of blood transfusion and surgical site infection, and increasing total discharge costs and length of stay.(3)
Ownership Table (as of 3/26/2019)
Holder # of Shares % Of CSO Fully Diluted
Shares (#)
Fully Diluted
Shares (%)
Michael Chermak (Chairman & CEO) 5,359,223 18.1% 5,359,223 14.9%
Barry Hollander (CFO) 1,000,000 3.4% 1,000,000 2.8%
Thomas McLeer (COO & Director) 15,000 0.1% 15,000 0.0%
Eric Siu (Founder) 10,854,987 36.6% 10,854,987 30.2%
Salman Chaudhry(1) 2,685,790 9.1% 2,685,790 7.5%
RWO Consulting 5,000,000 16.9% 5,000,000 13.9%
Total Insiders 24,915,000 84.1% 24,915,000 69.3%
Public Float(2) 4,715,446 15.9% 11,062,778 30.7%
TOTAL 29,630,446 100.0% 35,977,778 100.0%
Capitalization Table (as of 3/26/2019)
Security Common Stock
Equivalent Held
Weighted Average
Conversion / Exercise Price
Common Stock 29,630,446
Convertible Debt 6,000,000 $0.25
Warrants 347,332 $1.50
AI
